Gilead Sciences stock in focus after new Livdelzi evidence

Gilead Sciences reported detailed Phase 3 IDEAL results for Livdelzi on Thursday, November 5, 2026, saying the treatment produced sustained alkaline phosphatase normalization in a broader primary biliary cholangitis population. The company said it will engage with global regulatory authorities based on the findings.

According to the Gilead investor release, 75.4% of participants receiving Livdelzi reached the composite ALP normalization endpoint at Week 52, compared with 16.1% receiving placebo. The endpoint required ALP at or below the upper limit of normal and at least a 15% reduction from baseline.

Earlier response supports broader use

The response emerged after one month, when 52.3% of Livdelzi-treated participants met the endpoint versus 6.5% in the placebo group. IDEAL enrolled 96 adults with PBC whose ALP levels were above normal but below 1.67 times the upper limit of normal despite ursodeoxycholic acid treatment or because of intolerance.

Gilead said the safety profile was consistent with earlier Livdelzi studies and that no new safety concerns emerged. Serious adverse events occurred in 3.1% of Livdelzi-treated participants and 12.9% of placebo recipients; none were considered related to the trial drug.

Stock context for investors

The real-time quote of Gilead Sciences stock was 150.19 euros on Lang & Schwarz at 17:04 CET on Friday, November 6, 2026. That was 3.15% below the 155.07 euros cited in the comparable premarket report published on November 5, 2026, at 08:18 CET.

US equities provide the broader market setting for Gilead Sciences; see current market reports.

More news and analyses on Gilead Sciences stock.